BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38302780)

  • 21. Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer.
    Qiao W; Guo W; Liu Q; Guo X; Deng M
    Ann Diagn Pathol; 2023 Jun; 64():152125. PubMed ID: 36822053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer.
    Yang ZJ; Xin F; Chen ZJ; Yu Y; Wang X; Cao XC
    BMC Cancer; 2024 Jan; 24(1):134. PubMed ID: 38273267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathological complete response rates with pertuzumab-based neoadjuvant chemotherapy in breast cancer: A single-center experience.
    Matthews CM; Nymberg K; Berger M; Vargo CA; Dempsey J; Li J; Ramaswamy B; Reinbolt R; Sardesai S; Wesolowski R; Williams N; Lustberg M
    J Oncol Pharm Pract; 2020 Apr; 26(3):572-579. PubMed ID: 31256745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.
    Li XR; Liu M; Zhang YJ; Wang JD; Zheng YQ; Li J; Ma B; Song X
    Med Oncol; 2011 Dec; 28 Suppl 1():S31-8. PubMed ID: 20844986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
    Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
    Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive value of serum anti-p53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients.
    Bao H; Yu D; Wang J; Qiu T; Yang J; Wang L
    Anticancer Drugs; 2008 Mar; 19(3):317-23. PubMed ID: 18510179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD10 expression as a potential predictor of pathological complete response in ER-negative and triple-negative breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.
    Dimitrov G; Shousha S; Troianova P
    Exp Mol Pathol; 2024 Feb; 135():104885. PubMed ID: 38281565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes?
    Sueta A; Yamamoto Y; Hayashi M; Yamamoto S; Inao T; Ibusuki M; Murakami K; Iwase H
    Surgery; 2014 May; 155(5):927-35. PubMed ID: 24582496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
    Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
    J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
    Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
    Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma.
    Peng JH; Zhang X; Song JL; Ran L; Luo R; Li HY; Wang YH
    Medicine (Baltimore); 2019 Jan; 98(2):e13554. PubMed ID: 30633152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
    Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy.
    Osako T; Horii R; Matsuura M; Ogiya A; Domoto K; Miyagi Y; Takahashi S; Ito Y; Iwase T; Akiyama F
    J Cancer Res Clin Oncol; 2010 Feb; 136(2):233-41. PubMed ID: 19685074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G
    Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
    Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
    J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer.
    Ding Y; Ding K; Qian H; Yu X; Zou D; Yang H; Mo W; He X; Zhang F; Qin C; Zheng Y; Ding X
    PLoS One; 2020; 15(4):e0231895. PubMed ID: 32298374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulatory effect of neoadjuvant chemotherapy on the prognosis of patients with breast cancer.
    Trifunovic J; Memisevic N; Nikolin B; Salma S; Dugandzija T; Vidovic V
    J BUON; 2017; 22(2):638-643. PubMed ID: 28730768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prognostic significance of Ki-67 expression before and after neoadjuvant chemotherapy in different biological breast cancer phenotypes].
    Liu Y; Zhang X; Yu F; Liu J; Zhang M; Zhang S; Hao X; Zhang J
    Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):671-6. PubMed ID: 25564057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis.
    Chen X; He C; Han D; Zhou M; Wang Q; Tian J; Li L; Xu F; Zhou E; Yang K
    Future Oncol; 2017 Apr; 13(9):843-857. PubMed ID: 28075166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.
    Zhou B; Yang DQ; Xie F
    Chin Med J (Engl); 2008 Mar; 121(5):387-91. PubMed ID: 18364105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.